DOCTOR'S VIEW ARCHIVE
Tegaserod (Zelnorm)...New Drug for Irritable Bowel Syndrome
NOTE: On March 30, 2007 the FDA notified healthcare professionals and patients that Novartis has agreed to discontinue marketing Zelnorm, a drug used for the short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 years of age with chronic constipation. FDA analysis of safety data pooled from 29 clinical trials involving over 18,000 patients showed an excess number of serious cardiovascular adverse events, including angina, heart attacks, and stroke, in patients taking Zelnorm compared to patients given placebo. Patients taking Zelnorm should contact their healthcare professional to discuss treatment alternatives and seek emergency medical care if they experience severe chest pain, shortness of breath, sudden onset of weakness or difficulty walking or talking, or other symptoms of a heart attack or stroke. Healthcare professionals should assess their patients and transition them to other therapies as appropriate. Click Here to read the entire FDA Press Release.
The United States Food and Drug Administration (FDA) has approved tegaserod (Zelnorm), the first drug for the treatment of abdominal pain and constipation in patients with the irritable bowel syndrome (IBS).
What is IBS?
IBS is a functional disorder of the intestines and its nerves; it may be caused by either abnormal motility (abnormal contractions) of the intestinal muscles or abnormally sensitive nerves in the intestines (visceral hyper-sensitivity). IBS is more difficult to diagnose than diseases with structural abnormalities. (Structural abnormalities are abnormalities that can be "seen" by examinations such as x-ray or endoscopy such as ulcers, infections, colitis, and cancers.)
While IBS is not life-threatening, symptoms of IBS can have a significant impact on a person's quality of life and can even be debilitating. For example, a patient with frequent diarrhea and an urgent need to have a bowel movement after meals may avoid eating out; and patients who develop bloating and abdominal pain after meals may develop a fear of eating.
What causes IBS?
What is the traditional treatment of IBS?